🔗 Share this article

The first new treatments for gonorrhoea in decades are being viewed as a "major milestone" in the battle against drug-resistant strains of the infection, according to researchers.

A Global Public Health Issue

Cases of gonorrhoea are escalating around the world, with figures suggesting in excess of 82 million instances each year. Especially elevated rates are seen in Africa and countries within the World Health Organization's designated area, which includes China and Mongolia to New Zealand. Within England, cases have hit a all-time high, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of novel therapies for gonorrhoea is an significant and necessary development in the reality of increasing worldwide cases, escalating drug resistance and the extremely scarce therapeutic options presently on offer.”

Medical experts are particularly alarmed about the rise in treatment-resistant strains. The global health body has listed it as a "high-priority threat". Ongoing monitoring revealed that the effectiveness of key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Treatment Options Gain Authorization

One new antibiotic, also known as Nuzolvence, was approved by the American regulatory agency in December for use against gonorrhoea. This infection can lead to serious health problems, including infertility. Researchers believe that specific application of this new drug will help hinder the spread of drug resistance.

Gepotidacin, developed by the pharmaceutical company GSK, was also approved in close succession. This medication, which is also used to treat UTIs, was proven in research to be successful in treating superbug versions of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin emerged from a new, not-for-profit approach for medication research. The charitable organization GARDP partnered with the drug firm Innoviva to bring it to fruition.

“This milestone marks a major breakthrough in the treatment of superbug gonorrhoea, which until now has been staying ahead of medical innovation.”

Clinical Trial Results and Global Access

Based on results detailed in a major medical journal, zoliflodacin successfully treated the vast majority of cases of the STI. This establishes an equal footing with the typical regimen, which involves two antibiotics. The trial involved over 900 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, GARDP has the ability to make available and distribute the drug in many developing nations.

Medical professionals directly involved have shared hope. Having a easy-to-administer therapy such as this is seen as a "revolutionary step" for managing the epidemic. This is viewed as essential to alleviate the strain of the infection for patients and to prevent the spread of untreatable gonorrhoea around the world.